From: Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis
Patient characteristics | Visit 1 (baseline) | Visit 2 (follow-up) | ||||
---|---|---|---|---|---|---|
Minimum clinically important improvement patient group* | PÂ value** | Minimum clinically important improvement patient group* | P value** | |||
MCII+ (n = 12) | MCII− (n = 20) | MCII+ (n = 12) | MCII− (n = 20) | |||
Duration between visits (days), median [Q1, Q3]a | - | - | - | 363.0 [302.5, 377.5] | 252.0 [212.0, 341.3] | 0.08 |
Sex | Â | Â | 0.70 | Â | Â | 0.70 |
 Female, n (%) | 7 (58.3) | 14 (70.0) |  | 7 (58.3) | 14 (70.0) |  |
 Male, n (%) | 5 (41.7) | 6 (30.0) |  | 5 (41.7) | 6 (30.0) |  |
Age, mean ± s.d. | 68.0 ± 12.8 | 63.2 ± 9.7 | 0.09 | 68.9 ± 13.1 | 64.0 ± 9.7 | 0.09 |
 < 64 years, n (%) | 3 (25.0) | 10 (50.0) | 0.27 | 3 (25.0) | 10 (50.0) | 0.27 |
 ≥ 64 years, n (%) | 9 (75.0) | 10 (50.0) | 9 (75.0) | 10 (50.0) | ||
Smoking status | Â | Â | 0.52 | Â | Â | 0.27 |
 Smoker, n (%) | 0 (0) | 2 (10.0) |  | 0 (0) | 3 (15.0) |  |
 Non-smoker, n (%) | 12 (100) | 18 (90.0) |  | 12 (100) | 17 (85.0) |  |
Clinical measurements | Â | Â | Â | Â | Â | Â |
 bCDAI, median [Q1, Q3] | 19.8 [12.6, 30.1] | 9.3 [6.4, 13.7] | 0.03 | 2.7 [1.0, 7.7] | 14.0 [10.1, 21.7] | 1.9 × 10−3 |
 ΔCDAI, median [Q1, Q3] | - | - | - | − 15.1 [− 19.2, − 10.0] | 2.7 [− 0.2, 9.8] | 6.9 × 10−6 |
 cHAQ, median [Q1, Q3] | 0.6 [0.4, 0.9] | 0.8 [0.3, 1.1] | 0.57 | 0.4 [0.3, 0.8] | 0.7 [0.4, 1.2] | 0.09 |
 Pain (VASd 0–100 mm), median [Q1, Q3] | 41.0 [11.8, 67.8] | 26.5 [14.8, 56.3] | 0.61 | 9.5 [8.0, 36.0] | 63.0 [31.8, 78.5] | 2.8 × 10−3 |
 28-swollen joint count (SJC), median [Q1, Q3] | 6.5 [0.0, 13.3] | 1.5 [0.0, 4.3] | 0.12 | 0.0 [0.0, 2.0] | 1.0 [0.8, 4.8] | 0.08 |
 28-tender joint count (TJC), median [Q1, Q3] | 4.5 [0.0, 15.0] | 1.5 [0.8, 5.3] | 0.45 | 0.0 [0.0, 0.5] | 3.0 [2.0, 9.0] | 0.01 |
 ept_vas, median [Q1, Q3] | 45.5 [28.8, 59.0] | 28.0 [14.5, 52.3] | 0.56 | 10.5 [8.0, 35.0] | 49.0 [32.0, 71.3] | 6.3 × 10−3 |
 fmd_vas, median [Q1, Q3] | 37.5 [21.3, 55.0] | 20.0 [10.0, 25.0] | 0.06 | 5.0 [0.0, 12.5] | 25.0 [8.8, 50.0] | 0.01 |
Rheumatoid factor (RF) | Â | Â | 0.43 | Â | Â | 0.43 |
 Positive, n (%) | 8 (66.7) | 8 (40.0) |  | 8 (66.7) | 8 (40) |  |
 Negative, n (%) | 3 (25.0) | 7 (35.0) |  | 3 (25.0) | 7 (35.0) |  |
 not available | 1 (8.3) | 5 (25.0) |  | 1 (8.3) | 5 (25.0) |  |
Anti-citrullinated protein antibodies (ACPA) | Â | Â | 0.44 | Â | Â | 0.44 |
 Positive, n (%) | 9 (75.0) | 10 (50.0) |  | 9 (75.0) | 10 (50.0) |  |
 Negative, n (%) | 3 (25.0) | 8 (40.0) |  | 3 (25.0) | 8 (40.0) |  |
 Not available | 0 (0) | 2 (10.0) |  | 0 (0) | 2 (10.0) |  |
gCRP (mg/L), median [Q1, Q3] | 5.9 [2.9, 18.3] | 2.9 [2.9, 5.1] | 0.06 | 2.9 [2.9, 4.3] | 2.9 [2.9, 10.0] | 0.77 |
Treatment use | Â | Â | Â | Â | Â | Â |
 hbDMARDs (user), n (%) | 6 (50.0) | 9 (45.0) | 1 | 5 (41.7) | 8 (40.0) | 1 |
 icsDMARDs (user), n (%) | 11 (91.7) | 17 (85.0) | 1 | 11 (91.7) | 16 (80.0) | 0.63 |
 Prednisone (user), n (%) | 6 (50.0) | 9 (45.0) | 1 | 5 (41.7) | 9 (45) | 1 |